Treatment-Resistant Epilepsy
Human Clinical Evidence in Treatment-Resistant Pediatric Epilepsy
Research overview
Better Cann Pharmaceutical was among the early Israeli companies involved in multi-center clinical research involving children and adolescents with severe, treatment-resistant epilepsy.
The research examined the use of a standardized, plant-derived cannabinoid formulation in a pediatric population for whom existing therapies had not provided adequate seizure control.
Key results
- Any reduction in seizure frequency
- 89%
- 75–100% reduction
- 18%
- 50–75% reduction
- 34%
- 25–50% reduction
- 12%
Source: Tzadok et al., Seizure 35 (2016) 41–44. Retrospective, real-world cohort of 74 patients.
Outcomes
CBD-enriched treatment yielded a significant positive effect on seizure load. 66 of 74 children (89%) reported a reduction in seizure frequency.
Reported reductions: 75–100% in 18% of patients, 50–75% in 34%, 25–50% in 12%, and under 25% in 26%. Improvements were also observed in behavior, alertness, language and communication, motor skills, and sleep.
Figures are reported as published in Tzadok et al., Seizure 2016. As a retrospective, real-world study, results are described by parental report rather than a controlled trial design.
Safety observations
Adverse reactions included somnolence, fatigue, gastrointestinal disturbances, and irritability, leading to withdrawal of treatment in 5 patients. Five patients (7%) reported aggravation of seizures leading to withdrawal.
Study limitations
- Findings from a specific study population may not generalize to all patients or conditions.
- Exact study dates, participant numbers, institutions, investigators, and quantitative results are pending verification and appear as placeholders.
- This page is for scientific and corporate information only and is not a treatment recommendation.